Arabic Arabic English English French French German German
dark

MSD’s pneumococcal vaccine hits ‘key endpoints’ in Phase III

Phase III trial evaluated use in infants 42-90 days old Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Jazan: 571,000+ Beneficiaries of «Tetamman» Clinics and «Taakkad» Centers to Date

Next Post

Existing drug could offer hope as new therapy for ALL in children

Related Posts
Total
0
Share